Revolo Biotherapeutics to Lead Panel Discussion on the Future of Autoimmune Disease Treatment

2 years ago

NEW ORLEANS, May 10, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that…

VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17

2 years ago

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology…

VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

2 years ago

Webinar on Tuesday, May 17, 2022 at 10:00 a.m. ETBRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc.…

Conformis, Inc. to Participate in the H.C. Wainwright Global Investment Conference

2 years ago

BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee…

Aveanna to Participate at the RBC Capital Markets Global Healthcare Conference

2 years ago

ATLANTA, May 10, 2022 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team…

AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion

2 years ago

– Facility in Alachua, Florida Is Expected to be Completed in the Fourth Quarter of 2022 – GAINESVILLE, Fla. and CAMBRIDGE,…

aTyr Pharma to Present at Upcoming Investor Conferences in May

2 years ago

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery…

CinCor Reports First Quarter Financial Results and Provides Corporate Update

2 years ago

Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data…

F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

2 years ago

Four Clinical Readouts Anticipated Throughout 2022Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American…

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

2 years ago

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9…